Schema-Root.org logo

 

  cross-referenced news and research resources about

 Genentech

Schema-Root.org logo
images:  google   yahoo YouTube
spacer

updated Sun. April 29, 2018

-
Genentech, part of pharma giant Roche, has been developing a pipeline of neuroscience drugs at a time when other pharmaceutical companies have largely left the space. Among those drugs are two treatments for Alzheimer's disease, a condition that hasn't had a new treatment for 15 years and has faced a number ...
Treatment with Ocrevus (ocrelizumab) shows sustained efficacy and an ability to improve cognition in patients with relapsing multiple sclerosis (MS), according to data being presented by Genentech, the drug's developer. The company will detail these findings in a series of oral and poster sessions at the ...

Seattle biotech Kineta will partner with big biotech company Genentech to make and sell a drug used to treat chronic pain, in a deal that could be worth more than $359 million for the Seattle company. Kineta announced Monday it made a deal with San Francisco-based Genentech to develop Kineta's ...
Kineta Chronic Pain LLC has inked a drug collaboration deal with pharmaceutical giant Genentech to develop non-opioid chronic pain treatment. The Seattle-based biotech, a subsidiary of Kineta Inc., received an undisclosed upfront payment as part of the deal and is eligible for milestone payments up to ...
More than two years after Genentech passed over its option to acquire Constellation Pharmaceuticals, the immuno-oncology company raised $100 million that will bankroll a cancer epigenetics candidate through clinical trials, as well as advance several pipeline prospects. Its work is based on epigenetics, ...
The five adults with hemophilia A who died while using Hemlibra (emicizumab-kxwh) to treat their disease did not die of causes related to the treatment, manufacturer Genentech said in a statement. "In each of these cases, the assessment of the treating physician or investigator was that the cause of ...

The Hemophilia Federation of America has put out a statement noting that Roche alerted them of the deaths of 5 patients who were taking their new drug Hemlibra, calculated to be the biggest single drug launch of the year. And according to Roche, the alert followed the death of two patients earlier this year ...
Young joined Genentech in 2006, a time when the historically antibody-focused firm was trying to establish equal expertise in small molecules. Michael Varney, who now leads R&D at Genentech, had championed bringing her into the fold, and she started out in medicinal chemistry. As the team grew, ...
Genentech researchers have found a chink in the armor of drug-resistant, gram-negative bacteria called the BamA enzyme, which is found in the bugs' outer membrane. And they've found a way to attack this protein with an antibody—an approach that they say could pave the way for a new class of ...
Law360 (April 24, 2018, 8:42 PM EDT) -- Genentech on Monday urged the Federal Circuit to affirm a California federal judge's tossing of claims that it induced others to infringe a patent covering treatments for conditions such as breast cancer, arguing that not only was the lower court correct to do so, but that it should ...
Law360 (April 24, 2018, 8:42 PM EDT) -- Genentech on Monday urged the Federal Circuit to affirm a California federal judge's tossing of claims that it induced others to infringe a patent covering treatments for conditions such as breast cancer, arguing that not only was the lower court correct to do so, but that it should ... cancer
Ocrevus (ocrelizumab), Genentech's humanized anti-CD20 monoclonal antibody, continues to show clear evidence that it helps to slow disease progression and enable better function — including in the hands and limbs — of relapsing multiple sclerosis (MS) and primary progressive multiple sclerosis ... cancer
(RTTNews.com) - Genentech, a member of the Roche Group ( RHHBY ), reported encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema, treatment with intravitreal RG7716 resulted in clinically meaningful and statistically significant improvements ... cancer
William Grossman has been appointed chief medical officer of Bellicum Pharmaceuticals (NASDAQ: BLCM). Grossman comes to the Houston biotech company from Genentech, where he was group medical director, cancer immunotherapy. Bellicum develops immunotherapies for cancers and blood ... cancer
Phase III IMmotion151 study showed Genentech's Tecentriq (atezolizumab) and Avastin (bevacizumab) reduced the risk of disease worsening or death by 26 percent in certain people with advanced kidney cancer. Genentech, a member of the Roche Group announced results from the positive Phase III ... cancer
Grossman officially joins the Houston-based biotech Monday after two-and-a-half years at Genentech/Roche, where he most recently served as medical director of its cancer immunotherapy program. That involved leading the development of PD-L1 inhibitor Tecentriq in gastrointestinal cancers, as well as ... cancer
On one side of South San Francisco's mayor and the other officials is the city's largest employer, biotech giant Genentech Inc., which is largely responsible for the biotech boom in South San Francisco. On the other is a pressing regional need for housing, especially affordable housing, that Oyster Point ... cancer

South San Francisco's largest employer put its mouth where its money is Thursday, formally urging city officials to block 1,200 units of housing near Genentech Inc.'s 10,000-campus. In a 98-page packet of information it submitted on the last day the city was accepting comments on the draft EIR for a ... cancer
Law360 (February 2, 2018, 9:43 PM EST) -- A California federal judge on Friday granted a motion by Genentech to toss a complaint brought by Amgen seeking to invalidate more than two dozen patents related to Genentech's cancer treatment Avastin, finding that Amgen was bypassing a negotiation scheme required by ... cancer
“Genentech has rested on a complex series of patents from two dozen patent families. As Celltrion has already demonstrated to Genentech, these allegations are wrong and the panoply of vague allegations are simply intended to interfere with Celltrion and Teva's entry into the market,” read the complaint. cancer
Carmot also has a discovery and licensing deal with Genentech, inked in 2016. The financial terms and specific targets were not disclosed, but the collab takes the same format as the Amgen deal, with Carmot providing therapeutic prospects and Genentech taking responsibility for development and ... cancer
Forty Seven Inc., a developer of immuno-oncology treatments spun out of Stanford University, has launched a pair of collaborations with pharma giants Merck KGaA and Genentech, a member of the Roche Group, to develop its lead candidate as part of combination therapies for a trio of cancer indications. cancer
Forty Seven has added Roche to its partner list for its CD47-targeted immuno-oncology candidate, with Roche's Genentech unit agreeing to sponsor two ... tumor and blood cancer, with Genentech funding trials of the antibody plus Tecentriq (atezolizumab) in bladder cancer and acute myeloid leukemia. cancer
Juno Therapeutics (NASDAQ: JUNO) has appointed Cindy Elkins to serve as chief information officer. Elkins comes to the Seattle cancer immunotherapy developer from Genentech, where she was vice president, IT, for the Americas. Before Genentech, Elkins worked at software and IT services firm Ariba. cancer
Genentech has filed a lawsuit in the Tokyo District Court in a bit to prohibit sales of a biosimilar product of antiCD20 monoclonal antibody Rituxan (rituximab), marketed in Europe as MabThera. Swiss pharma giant Roche's (ROG: SIX) biotech arm filed the suit against Novartis (NOVN: VX) subsidiary Sandoz ... cancer
After expanding its partnership with Syndax $SNDX earlier this week on their lead drug, Genentech has beefed up their pipeline of PD-L1 combos with a fresh pact with Stanford spinout Forty Seven. The biotech put out word that Genentech will combine their two checkpoint drugs for use against acute ... cancer
Law360, Los Angeles (January 11, 2018, 6:13 PM EST) -- A California federal judge on Thursday tentatively paused Amgen's suit seeking to invalidate more than two dozen patents related to Genentech's cancer treatment Avastin, saying he wanted to see whether a Delaware court will transfer infringement actions that ... cancer
Amgen paints a different picture as to the bad actor during the parties' negotiations pursuant to the Biologics Price Competition and Innovation Act. Shortly after Amgen received US Food and Drug Administration (FDA) approval for MVASI® (bevacizumab-awwb), a biosimilar to Genentech's Avastin®, both ... cancer
A Peninsula startup focusing on a hijacked "don't eat me" signal sent by cancer cells to the immune system will work with Genentech Inc. to take an experimental drugs into two clinical trial programs. Forty Seven Inc., a Menlo Park-based spinout of from the Stanford University labs of Irv Weissman, also said ... cancer
Amgen paints a different picture as to the bad actor during the parties' negotiations pursuant to the Biologics Price Competition and Innovation Act. Shortly after Amgen received US Food and Drug Administration (FDA) approval for MVASI® (bevacizumab-awwb), a biosimilar to Genentech's Avastin®, both ... cancer
Genentech's partnership with BioNTech, a German company developing personalized cancer vaccines, is an example of this. We recognized the scientific brilliance of what they were thinking, and they recognized our entrepreneurial spirit and experience in taking big leaps to successfully develop and ... cancer
It's been close to 5 years since John Reed jumped from Sanford-Burnham to become the head of Roche's Basel-based pRED organization. And only now is the big drug research group he leads getting a closeup after years spent watching his colleagues at gRED — Genentech — steal the show with a ... cancer
Genentech, like Sanofi before it, has jumped into bed with DiCE to access a platform designed to broaden the range of targets that can be hit with small molecules. Initially, DiCE has sought to prove the credentials of the platform by designing small molecules that interrupt protein-protein interfaces. cancer
Monthly intravitreal injections of either 1.5 mg or 6 mg of RG7716 or of 0.3 mg Lucentis (ranibizumab, Genentech) were given to treatment-naive patients in the prospective, randomized, double-masked study. A total of 229 participants were enrolled at more than 90 sites in the U.S. Treatment continued ... cancer
As Novartis battles Regeneron for a piece of its blockbuster Eylea franchise, Roche/Genentech $RHHBY is coming up quietly with a next-gen bispecific antibody which posted encouraging Phase II results late Sunday. RG7716 is a dual anti-VEGF/anti-angiopoietin-2 antibody that targets retinal eye ... cancer
(RTTNews.com) - Genentech, a member of the Roche Group ( RHHBY ), reported encouraging results from the Phase II BOULEVARD study. In people with vision loss from diabetic macular edema (DME), treatment with intravitreal RG7716 demonstrated clinically meaningful visual acuity gains from ... cancer
Shortly after Amgen received US Food and Drug Administration (FDA) approval for MVASI® (bevacizumab-awwb), a biosimilar to Genentech's Avastin®, both parties filed competing lawsuits regarding patent infringement, as detailed in a previous LawFlash. Amgen filed a declaratory judgment lawsuit in the ... cancer
Syndax and Genentech began working together in 2015. That deal gave Syndax the chance to run a phase 1b/2 trial of its oral, immune regulatory cell-targeting entinostat and Tecentriq in patients with triple-negative breast cancer. Syndax is yet to complete enrollment in the phase 2 portion of the trial. cancer
... by the FDA for the treatment of adult patients with glioblastoma that progressed following prior therapy, according to its manufacturer, Genentech. ... and can be very difficult to treat,” Sandra Horning, MD, chief medical officer and head of Global Product Development at Genentech, said in a statement. cancer
“At Genentech, the development opportunities are so numerous and varied that it's almost overwhelming. I feel empowered to explore my genuine interests and to use company time to give back to the local community in a manner that's meaningful to me.” “I genuinely care about the professional development and personal ... cancer
Besides its own work, largely funded by $1 million annually from the Howard Hughes Medical Institute, the lab is working with South San Francisco's Calico LLC, a Google-backed company led by former Genentech CEO Art Levinson, on a drug to reverse memory loss. Less well known is the Walter lab's ... cancer
On May 1, the U.S. Court of Appeals for the Third Circuit affirmed the dismissal of Petratos v. Genentech, 855 F.3d 481 (3d Cir. 2017) (Petratos), and joined several other circuits in recognizing the heightened False Claims Act (FCA) materiality standard set forth in last year's landmark Supreme Court case, ... cancer
After a decade in the hands researchers and drug developers in Japan, a promising drug for treating hemophilia A was headed to South San Francisco, and perhaps no one was happier than Dr. Gallia Levy. Levy, who as a hematologist has spent her career studying bleeding disorders, saw the drug ... cancer
With Hemlibra, granted priority review, orphan drug and breakthrough therapy designations by the FDA, Genentech is seeking to revolutionize treatment in the hemophilia A space. Prepared for an imminent launch, the company set the price at a wholesale acquisition cost (WAC) of approximately $482,000 for the first year ... cancer
Arvinas first landed a deal with Genentech two years ago, at which time more than $300 million in milestones were up for grabs. That deal covered multiple disease targets. But Genentech has now decided it wants to use Arvinas' technology even more broadly, prompting it to return to the deal table to ... cancer
VACAVILLE — Genentech will lay off 130 people by the end of the year, all of them coming from its Vacaville facility, according to the biotech giant. “We are making this organizational change in response to current and anticipated production requirements, the volumes required for some of our new medicine ... cancer
AC Immune SA (NASDAQ: ACIU) today announced that Genentech, a member of the Roche Group, has dosed the first patient in a Phase 2 ... cancer
Expect initial patient enrollment in the fourth quarter 2017 in a previously announced second collaboration agreement with Genentech to ... cancer
It shows what Genentech, a division of Roche, calls SELs, or slowly evolving lesions. SELs may be markers to detect disease activity that's ... cancer
The issue presented to us is whether Genentech's employee, Ong, was acting within the scope of his employment when he was involved in the ... cancer


 

news and opinion


 


 


 


 


schema-root.org

     genentech

Biotechnology:
     galapagos
     genentech